Cargando…
HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
HCV infection is one of the main reasons for liver cirrhosis and hepatocellular carcinoma. In recent years, one finds more and more extrahepatic manifestations of HCV infection, including its possible influence on the development of diabetes. In the presented work, one finds the frequency analysis o...
Autores principales: | Rajewski, Paweł, Zarębska-Michaluk, Dorota, Janczewska, Ewa, Gietka, Andrzej, Mazur, Włodzimierz, Tudrujek-Zdunek, Magdalena, Tomasiewicz, Krzysztof, Belica-Wdowik, Teresa, Baka-Ćwierz, Barbara, Dybowska, Dorota, Halota, Waldemar, Lorenc, Beata, Sitko, Marek, Garlicki, Aleksander, Berak, Hanna, Horban, Andrzej, Orłowska, Iwona, Simon, Krzysztof, Socha, Łukasz, Wawrzynowicz-Syczewska, Marta, Jaroszewicz, Jerzy, Deroń, Zbigniew, Czauż-Andrzejuk, Agnieszka, Citko, Jolanta, Krygier, Rafał, Piekarska, Anna, Laurans, Łukasz, Dobracki, Witold, Białkowska, Jolanta, Tronina, Olga, Wietlicka-Piszcz, Magdalena, Pawłowska, Małgorzata, Flisiak, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780546/ https://www.ncbi.nlm.nih.gov/pubmed/35054072 http://dx.doi.org/10.3390/jcm11020379 |
Ejemplares similares
-
Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022) -
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018) -
Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021) -
Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019) -
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)